In order to maintain the trust of the company’s stakeholders, Orphazyme is committed to ensure transparent and good corporate governance. As a company listed on Nasdaq Copenhagen A/S, Orphazyme is subject to the Recommendations on Corporate Governance.
The Recommendations on Corporate Governance are best practice guidelines for the management of companies admitted to trading on a regulated market. Orphazyme intends to comply with the Recommendations on Corporate Governance in all material respects, however, due to the current size of the Company and the nature of its present operations, the company has opted to deviate from the Recommendations in the following areas:
- Orphazyme has decided only to publish annual reports and half-yearly financial reports;
- the annual report does not include information on individual board members’ participation in board meetings;
- the general conclusion of the latest evaluation of the Board of Directors is not described in the annual report, but is accounted for by the Chairman at the annual general meeting; and
- share-based remuneration is offered to the board of directors and have a maturity of one year from the date of allocation.
Orphazyme’s corporate governance statement includes a summary of the company’s governance structure, a description of internal control and financial reporting procedures, Orphazyme’s position on the Recommendations on Corporate Governance as well as a complete list of the company’s comments to recommendations that the company has opted to deviate from.
The corporate governance statement and other key documents are available here.